Clinical Scenarios
==================

The test is designed both for preconception carrier testing of couples wishing to start a family and for molecular diagnosis in children suspected of being affected by a recessive childhood disease. The published (research) version of the test included 448 childhood recessive illnesses with severe clinical manifestations[@ref1]. A revised panel is undergoing clinical validation for use as a laboratory developed test (LDT) with an intention of being offered via a laboratory regulated by the Clinical Laboratory Improvement Amendments (CLIA). The clinical panel contains 595 childhood recessive diseases that are deemed to meet American College of Medical Genetics (ACMG) criteria for implementation of genetic testing for ultra-rare disorders[@ref2]. Validation of analytic utility is being performed for the clinical scenarios detailed below prior to test offering. Initial validation of clinical utility and cost effectiveness will occur over the next year.

1\. Preconception carrier testing for recessively inherited diseases of childhood.

Prepregnancy carrier testing is currently offered to couples desiring to start a family in order to provide individualized genetic counseling about risk of conceiving a child affected by a specific recessively inherited diseas[@ref3] [@ref4]. The test performs preconception carrier testing for 595 recessive diseases simultaneously and three target populations are envisaged:

i\. [Couples undergoing *in vitro* fertilization (IVF) procedures]{.ul}. Testing of couples, pretesting of sperm and egg donors and genetic counseling is of utility for reduction in risk of having an affected child. Given the economics of IVF, the incremental cost of carrier testing is unlikely to be a barrier to adoption[@ref5]. Screening of sperm and oocyte donors has lower counseling burden than other clinical scenarios[@ref6]. Further, the motivation of couples undergoing IVF procedures is anticipated to facilitate adoption. Since testing is performed before conception, some of the ethical concerns of carrier testing in other clinical scenarios are not relevant[@ref3] [@ref6]. We are not aware of published studies of efficacy in this target population. It should be noted that knowledge of mutations in many of the 595 diseases is incomplete and testing is anticipated to reduce but not eliminate the risk of an affected child.

ii\. [Individuals and populations at high risk of recessive disorders]{.ul}. Examples include populations with genetic bottlenecks and / or higher rates of consanguinity. Ashkenazi Jewish populations, Arab populations, Amish populations and individuals with a family history of recessive diseases are examples. Preconception testing of motivated populations for recessive disease mutations, together with education and genetic counseling of carriers, can dramatically reduce disease incidence in a generation. The broad rationale is the success of testing north American Ashkenazi Jewish populations for carrier status of Tay-Sachs disease (TSD; Mendelian Inheritance in Man accession number OMIM\# 272800)[@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13].

iii.[General population testing]{.ul}. Given a recent report that we each harbor an average of 2.8 known recessive severe childhood disease mutations[@ref1], there is theoretical utility of voluntary carrier testing in general populations[@ref14]. The broad rationale is the success of general population testing for carrier status of cystic fibrosis \[CF, OMIM\#219700\][@ref12] [@ref13] [@ref15] [@ref16] [@ref17] [@ref18] [@ref19]. Practical clinical utility requires a). the cost to be low, b). provision of pre- and post-test genetic counseling (including delineation of the potential benefits and harms of carrier test results) and, c). protections for confidentiality, privacy and against stigmatization or discrimination. The ideal age for recessive disease screening is in early adulthood and before pregnancy. In the US, preconception carrier testing is hospital-based, whereas community-based testing has had success in Canada and Australia[@ref9] [@ref19] [@ref20] [@ref21] [@ref22]. Community-based population testing has advantages over testing in a hospital setting, where information about carrier testing often is communicated during pregnancy or after the birth of an affected child[@ref9] [@ref19] [@ref20] [@ref21] [@ref22]. Community-based carrier testing has had high uptake, without apparent stigma or discrimination and with substantial reductions in the frequencies of tested disorders[@ref9] [@ref19] [@ref20] [@ref21] [@ref22]. Of note, the United Kingdom\'s Human Genetics Commission recently reported that it found no specific social, ethical or legal principles that would make preconception genetic testing within the framework of a population screening program unacceptable[@ref14].

Preconception carrier testing for 595 diseases is anticipated to be offered initially as an LDT in late 2011 in the first two clinical scenarios. Expansion to general population testing is anticipated subsequently upon demonstration of cost effectiveness and validation of clinical utility in targeted populations. Revision of national policies for carrier testing is anticipated to be needed in response to next-generation-sequencing based multiplexed tests such as this.

2\. Diagnostic testing in potentially affected children.

Diagnostic carrier testing is offered to affected children (via parents) suspected of having a recessively inherited disease in order to determine a definitive diagnosis and, thereby, individualize treatment and genetic counseling[@ref2]. The broad rationale is that the test is an extension of conventional, univariate, serial molecular genetic testing. However, conventional approaches have severe limitations: Hundreds of recessive illnesses exist for which conventional molecular diagnosis is technically feasible but not available. They are too uncommon for commercially-viable conventional genetic testing or blocking patents exist. As a result, knowledge of mutation spectrum, genotype-phenotype relationships and allele frequencies in diseases without molecular diagnosis are rudimentary, inhibiting development of investigational new drugs. Of those for which molecular tests are available, many present as progressive multisystem disorders, requiring lengthy and costly differential diagnosis in a conventional genetic testing scenario, exhausting resources of patients, families and physicians. Thus, typically, \<50% of patients undergoing conventional genetic testing receive a molecular diagnosis despite average testing cost per patient of \>\$10,000. Furthermore, serial univariate testing can take over a year, delaying timely intervention or counseling. It should be noted that our knowledge of mutations in many of the 595 diseases is incomplete and thus testing will not provide definitive diagnosis in all affected children. The scope of diagnostic use of the test is in differential diagnosis of affected children suspected of having one of the 595 diseases. The intended test use is in molecular diagnosis.

Test Description
================

The test is as described[@ref1], but has been modified for clinical testing as follows: Genomic DNA is prepared from patient EDTA-blood samples. 2.6 million nucleotides of target genomic regions, representing exons, intron boundaries and non-exonic mutation containing regions in 527 genes are enriched \~500-fold from the 3.16 billion nucleotide (nt) genome of each sample. Enrichment uses hybrid capture, in which tens of thousands of oligonucleotide probes capture 8,614 genomic DNA fragments, collectively comprising 592 disease genes. Patient DNA is fragmented, denatured and incubated with the oligonucleotides. The target-oligonucleotide hybrids are isolated by magnetic capture[@ref23]. Next generation sequencing of the enriched targets is performed with Illumina HiSeq and TruSeq sequencing-by-synthesis, yielding \~3 billion nucleotides of sequence per sample, each \~125 nucleotides long. Sequences are aligned to the reference human genome uniquely, covering each target nucleotide \~150 times. Alignment uses the algorithm GSNAP[@ref24] [@ref25], with parameters that have been optimized for clinical diagnostic use. Enrichment and sequencing are performed on multiplexed samples, which are disambiguated by molecular barcodes. \~1% of target nucleotides are not covered, while \~95% of target nucleotides have at least 16-fold sequence coverage. The majority of missed nucleotides are in high GC-content targets, are missed reproducibly, and are labelled as such. An automated bioinformatic decision tree is used to identify and genotype variations in the aligned sequences[@ref24] [@ref26] [@ref27] [@ref28] [@ref29] [@ref30]. Variants are retained if present in at least 8 sequences of quality score [\>]{.ul}25 and in exons with at least 16-fold sequence coverage[@ref24]. Variants detected in \>86% of reads are considered homozygous, while those present in 14-86% of reads are heterozygous. Variants are classified according to ACMG and other guidelines[@ref2] [@ref18] [@ref31] [@ref32] [@ref33] [@ref34] [@ref35], using literature knowledge as well as *in silico*tools, such as comparison with a variety of mutation and human variation databases, PolyPhen-2 and SIFT, to determine the pathogenicity of each variant. Pathogenic variants are assembled into genotypes and reported. For diagnostic testing, where variants are of uncertain significance, further evidence is sought, using additional *in silico* tools, literature evidence, clinico-pathologic correlation, confirmatory family studies or functional assays, as appropriate. In general, variant interpretation is identical to that performed using conventional molecular diagnostic assays with the exceptions that clinico-pathologic interpretation and masking of non-relevant genes are routine in diagnostic use of the assay and that \~90% of variant annotation and reporting is automated, facilitating interpretation and standardization of reporting. Reporting of variants differs in carrier testing of adults and diagnostic testing of children[@ref31]. Carrier testing reports carrier status in all genes. Diagnostic testing reports positive and negative results in genes relevant to the clinical presentation. Diagnostic testing in children does not report carrier status in genes that are not relevant to presentation[@ref31]. In a subset of cases, further communication between the laboratory director and ordering physician is necessary to guide additional studies and assist in interpretation.

Public Health Importance
========================

Mendelian diseases collectively affect 13 million people in the US, accounting for \~20% of infant mortality and \~18% of pediatric hospitalizations[@ref36] [@ref37] [@ref38] [@ref39] [@ref40].

Diagnostic testing in potentially affected children

Simultaneous diagnostic testing for 595 recessive childhood diseases is anticipated to have several public health impacts: 1). Extension of the prevention, diagnosis, and treatment benefits demonstrated for conventional genetic testing to hundreds of recessive diseases for which testing is not available today; 2). Reduction in time-to-diagnosis, particularly in illnesses where the differential diagnosis is broad and the conventional approach is serial univariate testing. Serial univariate testing can take over a year, delaying timely intervention or counseling. The initial turnaround time of the test will be 4 weeks. 3). Reduction in cost of diagnosis. The average cost per patient of serial univariate molecular diagnostic testing is \~\$10,000 at our institution. The test is anticipated to cost \~\$600. 4). Increased rate of definitive molecular diagnosis. Less than 50% of patients undergoing serial univariate molecular diagnostic testing receive a molecular diagnosis. This is anticipated to increase with test use, particularly in illnesses where the differential diagnosis is broad, such as mitochondrial myopathies or intellectual disability. Timely diagnosis of affected individuals has several potential benefits:

1\. Prevention of death or markedly diminished disease severity where curative treatments are available. Quite a large number of recessive diseases have specific therapies. Neonatal diagnosis and treatment of phenylketonuria (PKU) and congenital hypothyroidism prevent severe intellectual disability. Likewise, death is prevented in certain forms of congenital adrenal hyperplasia (CAH), medium chain acyl-coA dehydrogenase deficiency (MCAD), and galactosemia (OMIM \#230400).

2\. Genetic counseling of patients and families about risks for relatives and in additional offspring.

3\. Improvement in quality of life in disorders where treatments are ameliorative. While many recessive diseases lack curative treatments, timely diagnosis nevertheless allows specific interventions that can substantially improve quality of life. Such interventions may slow disease progression, lessen symptoms, prevent complications or improve function in affected organ systems.

4\. Substantial psychosocial benefits with respect to anxiety, self-image, uncertainty and lifestyle decisions.

5\. Multiplexed testing allows rule-out of differential diagnoses, decreasing unnecessary treatments.

Use of the research version of the test revealed that 27% of literature mutations are common polymorphisms or misannotated^1^. Thus, it is critical to establish a clinical grade mutation database for recessive illnesses. Implementation of the test for diagnosis in affected children will, with time, improve the quality and quantity of annotated mutations, particularly for diseases that for which no molecular test is available currently.

In addition, test results have a cumulative potential to inform an understanding of disease mechanisms. In each individual with a Mendelian disorder, the specific mutations impact the age of onset, disease severity, rates of progression, distribution of affected organs, complications, pleiotropy and outcomes. Only in diseases for which molecular diagnosis is undertaken can such knowledge be accumulated. A broad understanding of genotype-phenotype relationships can enable individualized care of patients with recessive diseases. This can potentially include individualized treatment intensity and prediction of disease progression, severity and likely complications. Thus, in the long term, the test, when performed in a research setting, can allow identification of genotype-phenotype relationships that allow conveyance of individualized diagnostic information.

Initial experience with the test has revealed the existence of novel modifier mutations and pleiotropy in patients with recessive illnesses (Kingsmore et al., submitted). Only through multiplexed molecular testing can such knowledge be accumulated. A broad understanding of modifier genes can further enable individualized care of patients with recessive diseases. Thus, in the long term, the test, when performed in a research setting, can allow identification of modifier genes that allow conveyance of individualized diagnostic information.

Finally, timely molecular diagnosis can allow intervention before organ decompensation, when treatment is likely to alter outcomes. Currently, study of new therapies for rare disorders are hampered by diagnosis after organ damage and low rates of ascertainment. Timely diagnosis can permit regional referral of affected individuals for specialized treatment.

It should be noted that substantiation of the potential public health impacts in prevention, diagnosis, or treatment of recessive childhood illnesses is needed. Such assessments should include measurement of cost effectiveness including costs of follow up of ambiguous test results and counseling.

Published Reviews, Recommendations and Guidelines
=================================================

Systematic evidence reviews

The emerging use of targeted sequencing of panels of genes, whole exome sequencing and whole genome sequencing for molecular diagnosis of Mendelian diseases was recently reviewed[@ref45].

Recommendations by independent group

Currently none.

Guidelines by professional groups

The United Kingdom\'s Human Genetics Commission recently reported guidance on preconception genetic testing within the framework of a population screening program[@ref14].

Evidence Overview
=================

Analytic Validity:

The 437 genes responsible for 448 childhood recessive diseases are listed in Table 1. Using genotyping cut-offs of 14% and 86% to differentiate homozygotes and heterozygotes and [\>]{.ul}20X nucleotide coverage and [\>]{.ul}10 reads of quality [\>]{.ul}20 to call a variant, the accuracy of the test for SNP genotyping was 98.8%, analytic sensitivity was 94.9% and analytic specificity was 99.99% for 92,106 SNPs in 26 samples genotyped both by high density arrays and the test[@ref1]. The positive predictive value (PPV) of the test for SNP genotyping was 99.96% and negative predictive value was 98.5%, as ascertained by array hybridization[@ref1]. As sequence depth increased from 0.7 to 2.7GB, test sensitivity increased from 93.9% to 95.6%, whereas PPV remained \~100%. Area under the curve (AUC) of the receiver operating characteristic (ROC) of the test for 92,106 SNP genotypes in 26 samples, when compared with array hybridization, was 0.99 when the number and % reads calling a SNP was varied.

For known substitution, indel, splicing, gross deletion and regulatory alleles in 76 samples, analytic sensitivity was 100% (113 of 113 known alleles). The higher sensitivity for detection of known mutations reflected manual curation. The twenty known indels were confirmed by PCR and Sanger sequencing. Of note, substitutions, indels, splicing mutations and gross deletions account for the vast majority (96%) of annotated mutations[@ref27].

Unexpectedly, 14 of 113 literature-annotated disease mutations were either incorrect or incomplete. PCR and Sanger sequencing confirmed that the 14 variants and genotypes called by the test were correct[@ref1].

Gross deletions were detected both by perfect alignment to mutant junction reference sequences and by local decreases in normalized coverage (normalized to total sequence generated). Eleven of eleven gross deletion mutations for which boundaries had been defined were identified[@ref1]. Further analytic validation of ability to detect and genotype gross deletions, gross insertions and complex rearrangements is required.

It should be noted that the clinical version of the test will feature several improvements that are anticipated to improve analytic sensitivity and specificity. These are: 1). Increased depth of sequencing to 3 GB per sample; 2). Automation of the sequencing library preparation and target enrichment; 3). Re-design of the target enrichment oligonucleotides; 4). Change in the variant detection parameters to [\>]{.ul}16X nucleotide coverage and [\>]{.ul}6 reads of quality [\>]{.ul}25 to call a variant; 5). Further refinement of alignment parameters to prevent variant detection solely at the ends of reads; 6). Increased library size to reduce overlap redundancy; 7). Improved sequencing-by-synthesis chemistry (TruSeq); 8). Improved HiSeq instrument specification. Repetition of analytic validation is ongoing in a CLIA-compliant laboratory setting.

Clinical Validity

There are no published systematic evidence reviews of test accuracy, reliability or predictive value in a clinical setting. Experience is being garnered with the use of whole exome or whole genome sequencing for molecular diagnosis of Mendelian diseases and was recently reviewed.

Clinical Utility

There are no published systematic evidence reviews or published clinical trials. Published experience was in a research setting and was not blinded to sample diagnosis[@ref1]. Test development and assessment of analytic and clinical validity and utility are ongoing.

Links
=====

http://www.beyondbatten.org/

http://www.ncgr.org/preventing-rare-genetic-diseases

http://hematite.ncgr.org/

www.sciencemag.org/content/331/6014/130.full

http://www.npr.org/2011/01/13/132908098/new-gene-test-screens-nearly-500-childhood-diseases
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Table 1
=======

  -------- ------------------------------------------------------------------------------- -----------
  OMIM\#   NAME                                                                            GENE
  102700   SEVERE COMBINED IMMUNODEFICIENCY, AR, T CELL-NEGATIVE,                          ADA
  102770   MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO                              AMPD1
  105830   ANGELMAN SYNDROME AS                                                            MECP2
  107400   PROTEASE INHIBITOR 1; PI                                                        SERPINA1
  124000   MITOCHONDRIAL COMPLEX III DEFICIENCY                                            BCS1L
  124000   MITOCHONDRIAL COMPLEX III DEFICIENCY                                            UQCRB
  124000   MITOCHONDRIAL COMPLEX III DEFICIENCY                                            UQCRQ
  133540   COCKAYNE SYNDROME, B; CSB                                                       ERCC6
  141800   HEMOGLOBIN\--ALPHA LOCUS 1; HBA1                                                HBA1
  141900   HEMOGLOBIN\--BETA LOCUS; HBB                                                    HBB
  145900   HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS. CMT3, CMT4F                         EGR2
  145900   HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS. CMT3, CMT4F                         MPZ
  145900   HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS. CMT3, CMT4F                         PMP22
  145900   HYPERTROPHIC NEUROPATHY OF DEJERINE-SOTTAS. CMT3, CMT4F                         PRX
  188055   THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE                             F5
  190685   DOWN SYNDROME                                                                   GATA1
  200100   ABETALIPOPROTEINEMIA; ABL                                                       MTTP
  200990   ACROCALLOSAL SYNDROME; ACLS                                                     GLI3
  201000   CARPENTER SYNDROME                                                              RAB23
  201450   ACYL-CoA DEHYDROGENASE, MEDIUM-CHAIN, DEFICIENCY OF                             ACADM
  201460   ACYL-CoA DEHYDROGENASE, LONG-CHAIN, DEFICIENCY OF                               ACADL
  201470   ACYL-CoA DEHYDROGENASE, SHORT-CHAIN, DEFICIENCY OF                              ACADS
  201475   ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN, DEFICIENCY OF                          ACADVL
  201710   LIPOID CONGENITAL ADRENAL HYPERPLASIA                                           CYP11A1
  201710   LIPOID CONGENITAL ADRENAL HYPERPLASIA                                           STAR
  201910   CONGENITAL ADRENAL HYPERPLASIA, 21-HYDROXYLASE DEFICIENCY                       CYP21A2
  202400   AFIBRINOGENEMIA, CONGENITAL                                                     FGA
  202400   AFIBRINOGENEMIA, CONGENITAL                                                     FGB
  202400   AFIBRINOGENEMIA, CONGENITAL                                                     FGG
  203500   ALKAPTONURIA                                                                    HGD
  203700   ALPERS DIFFUSE CEREBRAL DEGENERATION WITH HEPATIC CIRRHOSIS                     POLG
  203780   ALPORT SYNDROME, AR                                                             COL4A3
  203780   ALPORT SYNDROME, AR                                                             COL4A4
  203800   ALSTROM SYNDROME; ALMS                                                          ALMS1
  204200   CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3                                        CLN3
  204500   CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2                                        TPP1
  205100   AMYOTROPHIC LATERAL SCLEROSIS 2, JUVENILE; ALS2                                 ALS2
  206700   ANIRIDIA, CEREBELLAR ATAXIA, AND MENTAL DEFICIENCY                              PAX6
  207410   ANTLEY-BIXLER SYNDROME; ABS                                                     FGFR2
  207900   ARGININOSUCCINIC ACIDURIA                                                       ASL
  208000   ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY; GACI                           ENPP1
  208085   ARTHROGRYPOSIS, RENAL DYSFUNCTION, AND CHOLESTASIS                              VPS33B
  208150   FETAL AKINESIA DEATION SEQUENCE; FADS                                           RAPSN
  208400   ASPARTYLGLUCOSAMINURIA                                                          AGA
  208540   RENAL-HEPATIC-PANCREATIC DYSPLASIA; RHPD                                        NPHP3
  208900   ATAXIA-TELANGIECTASIA; AT                                                       ATM
  208920   EARLY-ONSET ATAXIA WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA                  APTX
  210210   3-METHYLCROTONYL-CoA CARBOXYLASE 2 DEFICIENCY                                   MCCC2
  210600   SECKEL SYNDROME 1                                                               ATR
  210900   BLOOM SYNDROME; BLM                                                             BLM
  211600   CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 1; PFIC1                         ATP8B1
  211750   C SYNDROME                                                                      CD96
  212065   CONGENITAL DISORDER OF GLYCOSYLATION, Ia; CDG1A                                 PMM2
  212066   CONGENITAL DISORDER OF GLYCOSYLATION, IIa; CDG2A                                MGAT2
  212720   MARTSOLF SYNDROME                                                               RAB3GAP2
  213700   CEREBROTENDINOUS XANTHOMATOSIS                                                  CYP27A1
  214150   CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1                                     ERCC6
  214450   GRISCELLI SYNDROME, 1; GS1                                                      MYO5A
  214500   CHEDIAK-HIGASHI SYNDROME; CHS                                                   LYST
  214950   BILE ACID SYNTHESIS DEFECT, CONGENITAL, 4                                       AMACR
  215045   CHONDRODYSPLASIA, BLOMSTRAND ; BOCD                                             PTH1R
  215100   RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, 1; RCDP1                                  PEX7
  215140   HYDROPS-ECTOPIC CALCIFICATION-MOTH-EATEN SKELETAL DYSPLASIA                     LBR
  215150   OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; OSMED                                      COL11A2
  215150   OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA; OSMED                                      COL2A1
  215600   CIRRHOSIS, FAMILIAL                                                             KRT18
  215600   CIRRHOSIS, FAMILIAL                                                             KRT8
  215700   CITRULLINEMIA, CLASSIC                                                          ASS1
  216400   COCKAYNE SYNDROME, A; CSA                                                       ERCC8
  216550   COHEN SYNDROME; COH1                                                            VPS13B
  217090   PLASMINOGEN DEFICIENCY, I                                                       PLG
  217400   CORNEAL DYSTROPHY AND PERCEPTIVE DEAFNESS                                       SLC4A11
  218000   AGENESIS OF THE CORPUS CALLOSUM WITH PERIPHERAL NEUROPATHY; ACCPN               SLC12A6
  219000   FRASER SYNDROME                                                                 FRAS1
  219000   FRASER SYNDROME                                                                 FREM2
  219100   CUTIS LAXA, AR, I                                                               EFEMP2
  219100   CUTIS LAXA, AR, I                                                               FBLN5
  219200   CUTIS LAXA, AR, II                                                              ATP6V0A2
  219700   CYSTIC FIBROSIS; CF                                                             CFTR
  219750   CYSTINOSIS, ADULT NONNEPHROPATHIC                                               CTNS
  219800   CYSTINOSIS, NEPHROPATHIC; CTNS                                                  CTNS
  219900   CYSTINOSIS, LATE-ONSET JUVENILE OR ADOLESCENT NEPHROPATHIC                      CTNS
  220111   LEIGH SYNDROME, FRENCH-CANADIAN ; LSFC                                          LRPPRC
  220290   DEAFNESS, AR 1A                                                                 GJB2
  220400   JERVELL AND LANGE-NIELSEN SYNDROME 1; JLNS1                                     KCNQ1
  222448   DONNAI-BARROW SYNDROME                                                          LRP2
  222600   DIASTROPHIC DYSPLASIA                                                           SLC26A2
  223900   NEUROPATHY, HEREDITARY SENSORY AND AUTONOMIC, III; HSAN3                        IKBKAP
  224050   CEREBELLAR HYPOPLASIA AND MENTAL RETARDATION                                    VLDLR
  224410   DYSSEGMENTAL DYSPLASIA, SILVERMAN-HANDMAKER ; DDSH                              HSPG2
  225320   EHLERS-DANLOS SYNDROME, AR, CARDIAC VALVULAR                                    COL1A2
  225410   EHLERS-DANLOS SYNDROME, VII, AR                                                 ADAMTS2
  225750   AICARDI-GOUTIERES SYNDROME 1; AGS1                                              TREX1
  225753   PONTOCEREBELLAR HYPOPLASIA 4; PCH4                                              TSEN54
  226600   EPIDERMOLYSIS BULLOSA DYSTROPHICA, AR; RDEB                                     COL7A1
  226650   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ                                  COL17A1
  226650   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ                                  ITGB4
  226650   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ                                  LAMA3
  226650   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ                                  LAMB3
  226650   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, NON-HERLITZ                                  LAMC2
  226670   EPIDERMOLYSIS BULLOSA SIMPLEX WITH MUSCULAR DYSTROPHY                           PLEC1
  226700   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ                                      LAMA3
  226700   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ                                      LAMB3
  226700   EPIDERMOLYSIS BULLOSA, JUNCTIONAL, HERLITZ                                      LAMC2
  226730   EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA                         ITGA6
  226730   EPIDERMOLYSIS BULLOSA JUNCTIONALIS WITH PYLORIC ATRESIA                         ITGB4
  226980   EPIPHYSEAL DYSPLASIA, MULTIPLE, WITH EARLY-ONSET DIABETES MELLITUS              EIF2AK3
  228600   FIBROMATOSIS, JUVENILE HYALINE                                                  ANTXR2
  228930   FIBULAR APLASIA OR HYPOPLASIA                                                   WNT7A
  229200   BRITTLE CORNEA SYNDROME; BCS                                                    ZNF469
  229600   FRUCTOSE INTOLERANCE, HEREDITARY                                                ALDOB
  230000   FUCOSIDOSIS                                                                     FUCA1
  230400   GALACTOSEMIA                                                                    GALT
  230500   GM1-GANGLIOSIDOSIS, I                                                           GLB1
  230600   GM1-GANGLIOSIDOSIS, II                                                          GLB1
  230800   GAUCHER DISEASE, I                                                              GBA
  230900   GAUCHER DISEASE, II                                                             GBA
  231000   GAUCHER DISEASE, III                                                            GBA
  231050   GELEOPHYSIC DYSPLASIA                                                           ADAMTSL2
  231530   3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY                                      HADH
  231550   ACHALASIA-ADDISONIANISM-ALACRIMA SYNDROME; AAA                                  AAAS
  231670   GLUTARIC ACIDEMIA I                                                             GCDH
  231680   MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD                                ETFA
  231680   MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD                                ETFB
  231680   MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD                                ETFDH
  232200   GLYCOGEN STORAGE DISEASE I                                                      G6PC3
  232220   GLYCOGEN STORAGE DISEASE Ib                                                     SLC37A4
  232240   GLYCOGEN STORAGE DISEASE Ic                                                     SLC37A4
  232300   GLYCOGEN STORAGE DISEASE II                                                     GAA
  232400   GLYCOGEN STORAGE DISEASE III                                                    AGL
  232500   GLYCOGEN STORAGE DISEASE IV                                                     GBE1
  235200   HEMOCHROMATOSIS; HFE                                                            HFE
  235200   HEMOCHROMATOSIS; HFE                                                            HFE2
  235550   HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY; VODI                       SP110
  236200   HOMOCYSTINURIA                                                                  CBS
  236250   HOMOCYSTINURIA DUE TO DEFICIENCY OF METHYLENETETRAHYDROFOLATE                   MTHFR
  236490   HYALINOSIS, INFANTILE SYSTEMIC                                                  ANTXR2
  236670   WALKER-WARBURG SYNDROME; WWS                                                    POMT1
  236670   WALKER-WARBURG SYNDROME; WWS                                                    POMT2
  236680   HYDROLETHALUS SYNDROME 1                                                        HYLS1
  237300   CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA                     CPS1
  237310   N-ACETYLGLUTAMATE SYNTHASE DEFICIENCY                                           NAGS
  238970   HYPERORNITHINEMIA-HYPERAMMONEMIA-HOMOCITRULLINURIA SYNDROME                     SLC25A15
  239000   PAGET DISEASE, JUVENILE                                                         TNFRSF11B
  240300   AUTOIMMUNE POLYENDOCRINE SYNDROME, I; APS1                                      AIRE
  241200   BARTTER SYNDROME, ANTENATAL, 2                                                  KCNJ1
  241410   HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM SYNDROME; HRD                        TBCE
  241510   HYPOPHOSPHATASIA, CHILDHOOD                                                     ALPL
  241520   HYPOPHOSPHATEMIC RICKETS, AR                                                    DMP1
  241550   HYPOPLASTIC LEFT HEART SYNDROME                                                 GJA1
  242300   ICHTHYOSIS, LAMELLAR, 1; LI1                                                    TGM1
  242500   ICHTHYOSIS CONGENITA, HARLEQUIN FETUS                                           ABCA12
  242860   IMMUNODEFICIENCY-CENTROMERIC INSTABILITY-FACIAL ANOMALIES SYNDROME              DNMT3B
  243500   ISOVALERIC ACIDEMIA; IVA                                                        IVD
  243800   JOHANSON-BLIZZARD SYNDROME; JBS                                                 UBR1
  244460   KENNY-CAFFEY SYNDROME, 1; KCS                                                   TBCE
  245200   KRABBE DISEASE                                                                  GALC
  245349   PYRUVATE DEHYDROGENASE E3-BINDING PROTEIN DEFICIENCY                            PDHX
  245400   LACTIC ACIDOSIS, FATAL INFANTILE                                                SUCLG1
  245660   LARYNGOONYCHOCUTANEOUS SYNDROME; LOCS                                           LAMA3
  246200   DONOHUE SYNDROME                                                                INSR
  246450   3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY                                 HMGCL
  248190   HYPOMAGNESEMIA, RENAL, WITH OCULAR INVOLVEMENT                                  CLDN19
  248500   MANNOSIDOSIS, ALPHA B, LYSOSOMAL                                                MAN2B1
  248600   MAPLE SYRUP URINE DISEASE Ia                                                    BCKDHA
  248600   MAPLE SYRUP URINE DISEASE, CLASSIC, IB                                          BCKDHB
  248600   MAPLE SYRUP URINE DISEASE III                                                   DLD
  248800   Marinesco-Sjogren Syndrome                                                      SIL1
  249000   MECKEL SYNDROME, 1; MKS1                                                        MKS1
  249100   FAMILIAL MEDITERRANEAN FEVER; FMF                                               MEFV
  249900   METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY                        PSAP
  250100   METACHROMATIC LEUKODYSTROPHY                                                    ARSA
  250250   CARTILAGE-HAIR HYPOPLASIA; CHH                                                  RMRP
  250620   BETA-HYDROXYISOBUTYRYL CoA DEACYLASE, DEFICIENCY OF                             HIBCH
  250950   3-METHYLGLUTACONIC ACIDURIA, I                                                  AUH
  251000   METHYLMALONIC ACIDURIA DUE TO METHYLMALONYL-CoA MUTASE DEFICIENCY               MUT
  251110   METHYLMALONIC ACIDURIA, cblB                                                    MMAB
  251260   NIJMEGEN BREAKAGE SYNDROME                                                      NBN
  251880   MITOCHONDRIAL DNA DEPLETION SYNDROME, HEPATOCEREBRAL                            C10ORF2
  251880   MITOCHONDRIAL DNA DEPLETION SYNDROME, HEPATOCEREBRAL                            DGUOK
  251880   MITOCHONDRIAL DNA DEPLETION SYNDROME, HEPATOCEREBRAL                            MPV17
  252150   MOLYBDENUM COFACTOR DEFICIENCY                                                  MOCS1
  252150   MOLYBDENUM COFACTOR DEFICIENCY                                                  MOCS2
  252500   MUCOLIPIDOSIS II ALPHA/BETA                                                     GNPTAB
  252600   MUCOLIPIDOSIS III ALPHA/BETA                                                    GNPTAB
  252650   MUCOLIPIDOSIS IV                                                                MCOLN1
  252900   MUCOPOLYSACCHARIDOSIS IIIA                                                      SGSH
  252930   MUCOPOLYSACCHARIDOSIS IIIC                                                      HGSNAT
  253200   MUCOPOLYSACCHARIDOSIS VI                                                        ARSB
  253220   MUCOPOLYSACCHARIDOSIS VII                                                       GUSB
  253230   MUCOPOLYSACCHARIDOSIS VIII                                                      GNS
  253250   MULIBREY NANISM                                                                 TRIM37
  253260   BIOTINIDASE DEFICIENCY                                                          BTD
  253280   MUSCLE-EYE-BRAIN DISEASE; MEB                                                   FKRP
  253280   MUSCLE-EYE-BRAIN DISEASE; MEB                                                   POMGNT1
  253290   MULTIPLE PTERYGIUM SYNDROME, LETHAL                                             CHRNA1
  253290   MULTIPLE PTERYGIUM SYNDROME, LETHAL                                             CHRND
  253290   MULTIPLE PTERYGIUM SYNDROME, LETHAL                                             CHRNG
  253300   SPINAL MUSCULAR ATROPHY, I; SMA1                                                SMN1
  253310   LETHAL CONGENITAL CONTRACTURE SYNDROME 1; LCCS1                                 GLE1
  253400   SPINAL MUSCULAR ATROPHY, III; SMA3                                              SMN1
  253550   SPINAL MUSCULAR ATROPHY, II; SMA2                                               SMN1
  253800   FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD                                    FKTN
  254780   MYOCLONIC EPILEPSY OF LAFORA                                                    EPM2A
  254780   MYOCLONIC EPILEPSY OF LAFORA                                                    NHLRC1
  254800   MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG                                   CSTB
  255110   CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LATE-ONSET                        CPT2
  255120   CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY                                     CPT1A
  255960   MYXOMA, INTRACARDIAC                                                            PRKAR1A
  256030   NEMALINE MYOPATHY 2; NEM2                                                       NEB
  256050   ATELOSTEOGENESIS, II; AOII                                                      SLC26A2
  256100   NEPHRONOPHTHISIS 1; NPHP1                                                       NPHP1
  256300   NEPHROSIS 1, CONGENITAL, FINNISH ; NPHS1                                        NPHS1
  256370   NEPHROTIC SYNDROME, EARLY-ONSET, WITH DIFFUSE MESANGIAL SCLEROSIS               WT1
  256550   NEURAMINIDASE DEFICIENCY                                                        NEU1
  256600   NEUROAXONAL DYSTROPHY, INFANTILE; INAD1                                         PLA2G6
  256710   ELEJALDE DISEASE                                                                MYO5A
  256730   CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1                                        PPT1
  256731   CEROID LIPOFUSCINOSIS, NEURONAL, 5; CLN5                                        CLN5
  256800   INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS; CIPA                        NTRK1
  256810   NAVAJO NEUROHEPATOPATHY; NN                                                     MPV17
  257200   NIEMANN-PICK DISEASE, A                                                         SMPD1
  257220   NIEMANN-PICK DISEASE, C1; NPC1                                                  NPC1
  257320   LISSENCEPHALY 2; LIS2                                                           RELN
  257980   ODONTOONYCHODERMAL DYSPLASIA; OODD                                              WNT10A
  258501   3-METHYLGLUTACONIC ACIDURIA, III                                                OPA3
  259700   OSTEOPETROSIS, AR 1; OPTB1                                                      TCIRG1
  259720   OSTEOPETROSIS, AR 5; OPTB5                                                      OSTM1
  259730   OSTEOPETROSIS, AR 3; OPTB3                                                      CA2
  259770   OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; OPPG                                        LRP5
  259775   RAINE SYNDROME; RNS                                                             FAM20C
  259900   HYPEROXALURIA, PRIMARY, I                                                       AGXT
  260000   HYPEROXALURIA, PRIMARY, II                                                      GRHPR
  260400   SHWACHMAN-DIAMOND SYNDROME; SDS                                                 SBDS
  261515   D-BIFUNCTIONAL PROTEIN DEFICIENCY                                               HSD17B4
  261600   PHENYLKETONURIA; PKU                                                            PAH
  261740   GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL                            PRKAG2
  262300   ACHROMATOPSIA 3; ACHM3                                                          CNGB3
  262600   PITUITARY DWARFISM III                                                          HESX1
  262600   PITUITARY DWARFISM III                                                          LHX3
  262600   PITUITARY DWARFISM III                                                          POU1F1
  262600   PITUITARY DWARFISM III                                                          PROP1
  263200   POLYCYSTIC KIDNEY DISEASE, AR; ARPKD                                            PKHD1
  263700   PORPHYRIA, CONGENITAL ERYTHROPOIETIC                                            UROS
  264350   PSEUDOHYPOALDOSTERONISM, I, AR; PHA1                                            SCNN1A
  264350   PSEUDOHYPOALDOSTERONISM, I, AR; PHA1                                            SCNN1B
  264350   PSEUDOHYPOALDOSTERONISM, I, AR; PHA1                                            SCNN1G
  264470   PEROXISOMAL ACYL-CoA OXIDASE DEFICIENCY                                         ACOX1
  264700   VITAMIN D-DEPENDENT RICKETS, I                                                  CYP27B1
  265000   MULTIPLE PTERYGIUM SYNDROME, ESCOBAR                                            CHRNG
  265100   PULMONARY ALVEOLAR MICROLITHIASIS                                               SLC34A2
  265120   SURFACTANT METABOLISM DYSFUNCTION, PULMONARY, 1; SMDP1                          SFTPB
  265380   NEWBORN PULMONARY HYPERTENSION, FAMILIAL PERSISTENT                             CPS1
  265450   PULMONARY VENOOCCLUSIVE DISEASE; PVOD                                           BMPR2
  265800   PYCNODYSOSTOSIS                                                                 CTSK
  266130   GLUTATHIONE SYNTHETASE DEFICIENCY                                               GSS
  266150   PYRUVATE CARBOXYLASE DEFICIENCY                                                 PC
  266200   PYRUVATE KINASE DEFICIENCY OF RED CELLS                                         PKLR
  266265   CONGENITAL DISORDER OF GLYCOSYLATION, IIc; CDG2C                                SLC35C1
  266900   SENIOR-LOKEN SYNDROME 1; SLSN1                                                  NPHP1
  267430   RENAL TUBULAR DYSGENESIS; RTD                                                   ACE
  267430   RENAL TUBULAR DYSGENESIS; RTD                                                   AGT
  267430   RENAL TUBULAR DYSGENESIS; RTD                                                   AGTR1
  267430   RENAL TUBULAR DYSGENESIS; RTD                                                   REN
  267450   RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS                              SFTPA1
  267450   RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS                              SFTPB
  267450   RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS                              SFTPC
  268300   ROBERTS SYNDROME; RBS                                                           ESCO2
  268800   SANDHOFF DISEASE                                                                HEXB
  269250   SCHNECKENBECKEN DYSPLASIA                                                       SLC35D1
  269920   INFANTILE SIALIC ACID STORAGE DISORDER                                          SLC17A5
  270200   SJOGREN-LARSSON SYNDROME; SLS                                                   ALDH3A2
  270400   SMITH-LEMLI-OPITZ SYNDROME; SLOS                                                DHCR7
  270450   INSULIN-LIKE GROWTH FACTOR I, RESISTANCE TO                                     IGF1
  270550   SPASTIC ATAXIA, CHARLEVOIX-SAGUENAY ; SACS                                      SACS
  271245   INFANTILE-ONSET SPINOCEREBELLAR ATAXIA; IOSCA                                   C10ORF2
  271900   CANAVAN DISEASE                                                                 ASPA
  271930   STRIATONIGRAL DEGENERATION, INFANTILE; SNDI                                     NUP62
  271980   SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY                                  ALDH5A1
  272300   SULFOCYSTEINURIA                                                                SUOX
  272800   TAY-SACHS DISEASE; TSD                                                          HEXA
  273395   TETRA-AMELIA, AR                                                                WNT3
  274150   THROMBOTIC THROMBOCYTOPENIC PURPURA, CONGENITAL; TTP                            ADAMTS13
  274270   DIHYDROPYRIMIDINE DEHYDROGENASE; DPYD                                           DPYD
  274600   PENDRED SYNDROME; PDS                                                           SLC26A4
  275100   HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 4; CHNG4                               TSHB
  275210   TIGHT SKIN CONTRACTURE SYNDROME, LETHAL                                         LMNA
  275210   TIGHT SKIN CONTRACTURE SYNDROME, LETHAL                                         ZMPSTE24
  276700   TYROSINEMIA, I                                                                  FAH
  276820   ULNA AND FIBULA, ABSENCE OF                                                     WNT7A
  276900   USHER SYNDROME, I                                                               MYO7A
  276901   USHER SYNDROME, IIA; USH2A                                                      USH2A
  276902   USHER SYNDROME, III; USH3                                                       CLRN1
  276904   USHER SYNDROME, IC; USH1C                                                       USH1C
  277300   SPONDYLOCOSTAL DYSOSTOSIS, AR 1; SCDO1                                          DLL3
  277400   METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC                                 MMACHC
  277440   VITAMIN D-DEPENDENT RICKETS, II                                                 VDR
  277460   VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED                                 TTPA
  277470   PONTOCEREBELLAR HYPOPLASIA 2A; PCH2A                                            TSEN54
  277580   WAARDENBURG-SHAH SYNDROME                                                       EDN3
  277580   WAARDENBURG-SHAH SYNDROME                                                       EDNRB
  277580   WAARDENBURG-SHAH SYNDROME                                                       SOX10
  277900   WILSON DISEASE                                                                  ATP7B
  278700   XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A; XPA                             XPA
  278730   XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD                             ERCC2
  278740   XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP E                                  DDB2
  278760   XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP F; XPF                             ERCC4
  278780   XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG                             ERCC5
  278800   DE SANCTIS-CACCHIONE SYNDROME                                                   ERCC6
  278800   DE SANCTIS-CACCHIONE SYNDROME                                                   XPA
  300004   CORPUS CALLOSUM, AGENESIS OF, WITH ABNORMAL GENITALIA                           ARX
  300018   DOSAGE-SENSITIVE SEX REVERSAL; DSS                                              NR0B1
  300048   INTESTINAL PSEUDOOBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, XLR                 FLNA
  300067   LISSENCEPHALY, XLR, 1; LISX1                                                    DCX
  300069   CARDIOMYOPATHY, DILATED, 3A; CMD3A                                              TAZ
  300100   ADRENOLEUKODYSTROPHY; ALD                                                       ABCD1
  300209   SIMPSON-GOLABI-BEHMEL SYNDROME, 2                                               OFD1
  300215   LISSENCEPHALY, XLR, 2 LISX2                                                     ARX
  300220   MENTAL RETARDATION, XLR, SYNDROMIC 10; MRXS10                                   HSD17B10
  300240   HOYERAAL-HREIDARSSON SYNDROME; HHS                                              DKC1
  300243   MENTAL RETARDATION, XLR, SYNDROMIC, CHRISTIANSON                                SLC9A6
  300291   ECTODERMAL DYSPLASIA, HYPOHIDROTIC, WITH IMMUNE DEFICIENCY                      IKBKG
  300301   OSTEOPETROSIS, LYMPHEDEMA, ECTODERMAL DYSPLASIA, ANHIDROSIS, IMMUNODEFICIENCY   IKBKG
  300322   LESCH-NYHAN SYNDROME; LNS                                                       HPRT1
  300352   CREATINE DEFICIENCY SYNDROME, XLR                                               SLC6A8
  300400   SEVERE COMBINED IMMUNODEFICIENCY, XLR; SCIDX1                                   IL2RG
  300472   AGENESIS OF CORPUS CALLOSUM WITH MENTAL RETARDATION, OCULAR COLOBOMA            IGBP1
  300523   ALLAN-HERNDON-DUDLEY SYNDROME AHDS                                              SLC16A2
  300672   EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2                                    CDKL5
  300673   ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS                         MECP2
  300755   AGAMMAGLOBULINEMIA, XLR XLA                                                     BTK
  301000   WISKOTT-ALDRICH SYNDROME; WAS                                                   WAS
  301040   α-THALASSEMIA/MENTAL RETARDATION SYNDROME,NONDELETION , XLR ATRX                ATRX
  301500   FABRY DISEASE                                                                   GLA
  301830   SPINAL MUSCULAR ATROPHY, XLR 2; SMAX2                                           UBA1
  301835   ARTS SYNDROME; ARTS                                                             PRPS1
  302045   CARDIOMYOPATHY, DILATED, 3B; CMD3B                                              DMD
  302060   BARTH SYNDROME; BTHS                                                            TAZ
  302950   CHONDRODYSPLASIA PUNCTATA 1, XLR RECESSIVE; CDPX1                               ARSE
  303100   CHOROIDEREMIA; CHM                                                              CHM
  303350   MASA SYNDROME                                                                   L1CAM
  304100   CORPUS CALLOSUM, PARTIAL AGENESIS OF, XLR                                       L1CAM
  304790   IMMUNODYSREGULATION, POLYENDOCRINOPATHY, AND ENTEROPATHY, XLR                   FOXP3
  305100   ECTODERMAL DYSPLASIA, HYPOHIDROTIC, XLR; XHED                                   EDA
  305900   GLUCOSE-6-PHOSPHATE DEHYDROGENASE; G6PD                                         G6PD
  306955   HETEROTAXY, VISCERAL, 1, XLR; HTX1                                              ZIC3
  307000   HYDROCEPHALUS DUE TO CONGENITAL STENOSIS OF AQUEDUCT OF SYLVIUS; HSAS           L1CAM
  308230   IMMUNODEFICIENCY WITH HYPER-IgM, 1; HIGM1                                       CD40LG
  308240   LYMPHOPROLIFERATIVE SYNDROME, XLR, 1; XLP1                                      SH2D1A
  308350   EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 1                                    ARX
  308370   INFERTILE MALE SYNDROME                                                         AR
  308930   LEIGH SYNDROME, XLR                                                             PDHA1
  309000   LOWE OCULOCEREBRORENAL SYNDROME; OCRL                                           OCRL
  309400   MENKES DISEASE                                                                  ATP7A
  309500   RENPENNING SYNDROME 1; RENS1                                                    PQBP1
  309520   LUJAN-FRYNS SYNDROME                                                            MED12
  310200   MUSCULAR DYSTROPHY, DUCHENNE ; DMD                                              DMD
  310400   MYOTUBULAR MYOPATHY 1; MTM1                                                     MTM1
  310600   NORRIE DISEASE; ND                                                              NDP
  311150   OPTICOACOUSTIC NERVE ATROPHY WITH DEMENTIA                                      TIMM8A
  311250   ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO                    OTC
  312060   PROPERDIN DEFICIENCY, XLR                                                       CFP
  312080   PELIZAEUS-MERZBACHER DISEASE; PMD                                               PLP1
  312700   RETINOSCHISIS 1, XLR, JUVENILE; RS1                                             RS1
  312750   RETT SYNDROME; RTT                                                              MECP2
  312863   COMBINED IMMUNODEFICIENCY, XLR; CIDX                                            IL2RG
  312920   SPASTIC PARAPLEGIA 2, XLR; SPG2                                                 PLP1
  314390   VACTERL ASSOCIATION WITH HYDROCEPHALUS, XLR                                     FANCB
  600060   DEAFNESS, NEUROSENSORY, AR 2; DFNB2                                             MYO7A
  600118   WARBURG MICRO SYNDROME; WARBM                                                   RAB3GAP1
  600121   RHIZOMELIC CHONDRODYSPLASIA PUNCTATA, 3; RCDP3                                  AGPS
  600143   CEROID LIPOFUSCINOSIS, NEURONAL, 8; CLN8                                        CLN8
  600501   ABCD SYNDROME                                                                   EDNRB
  600649   CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, INFANTILE                         CPT2
  600721   D-2-HYDROXYGLUTARIC ACIDURIA                                                    D2HGDH
  600737   INCLUSION BODY MYOPATHY 2, AR; IBM2                                             GNE
  600802   SEVERE COMBINED IMMUNODEFICIENCY, AR, T CELL- B CELL+, NK CELL-                 JAK3
  600972   ACHONDROGENESIS, IB; ACG1B                                                      SLC26A2
  601067   USHER SYNDROME, ID; USH1D                                                       CDH23
  601186   MICROPHTHALMIA, SYNDROMIC 9; MCOPS9                                             STRA6
  601378   CRISPONI SYNDROME                                                               CRLF1
  601451   NEVO SYNDROME                                                                   PLOD1
  601457   SEVERE COMBINED IMMUNODEFICIENCY, AR, T CELL-NEGATIVE,                          RAG1
  601457   SEVERE COMBINED IMMUNODEFICIENCY, AR, T CELL-NEGATIVE,                          RAG2
  601559   STUVE-WIEDEMANN SYNDROME                                                        LIFR
  601675   TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP                                       ERCC2
  601675   TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP                                       ERCC3
  601675   TRICHOTHIODYSTROPHY, PHOTOSENSITIVE; TTDP                                       GTF2H5
  601678   BARTTER SYNDROME, ANTENATAL, 1                                                  SLC12A1
  601705   T-CELL IMMUNODEFICIENCY, CONGENITAL ALOPECIA, AND NAIL DYSTROPHY                FOXN1
  601706   YEMENITE DEAF-BLIND HYPOPIGMENTATION SYNDROME                                   SOX10
  601780   CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6                                        CLN6
  601847   CHOLESTASIS, PROGRESSIVE FAMILIAL INTRAHEPATIC 2; PFIC2                         ABCB11
  602083   USHER SYNDROME, IF; USH1F                                                       PCDH15
  602088   NEPHRONOPHTHISIS 2; NPHP2                                                       INVS
  602390   HEMOCHROMATOSIS, JUVENILE; JH                                                   HAMP
  602390   HEMOCHROMATOSIS, JUVENILE; JH                                                   HFE2
  602398   DESMOSTEROLOSIS                                                                 DHCR24
  602473   ENCEPHALOPATHY, ETHYLMALONIC                                                    ETHE1
  602579   CONGENITAL DISORDER OF GLYCOSYLATION, Ib; CDG1B                                 MPI
  602771   RIGID SPINE MUSCULAR DYSTROPHY 1; RSMD1                                         SEPN1
  603147   CONGENITAL DISORDER OF GLYCOSYLATION, Ic; CDG1C                                 ALG6
  603358   GRACILE SYNDROME                                                                BCS1L
  603554   OMENN SYNDROME                                                                  DCLRE1C
  603554   OMENN SYNDROME                                                                  RAG1
  603554   OMENN SYNDROME                                                                  RAG2
  603585   CONGENITAL DISORDER OF GLYCOSYLATION, IIf; CDG2F                                SLC35A1
  603903   SICKLE CELL ANEMIA                                                              HBB
  604004   MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS; MLC                 MLC1
  604250   HEMOCHROMATOSIS, 3                                                              TFR2
  604320   SPINAL MUSCULAR ATROPHY, DISTAL, AR, 1; DSMA1                                   IGHMBP2
  604369   SIALURIA, FINNISH                                                               SLC17A5
  604377   CARDIOENCEPHALOMYOPATHY, FATAL INFANTILE, DUE TO CYTOCHROME c OXIDASE           SCO2
  604498   AMEGAKARYOCYTIC THROMBOCYTOPENIA, CONGENITAL; CAMT                              MPL
  605039   C-LIKE SYNDROME                                                                 CD96
  605253   NEUROPATHY, HYPOMYELINATING/CHARCOT-MARIE-TOOTH DISEASE, 4E                     EGR2
  605253   NEUROPATHY, HYPOMYELINATING/CHARCOT-MARIE-TOOTH DISEASE, 4E                     MPZ
  605355   NEMALINE MYOPATHY 5; NEM5                                                       TNNT1
  605407   SEGAWA SYNDROME, AR                                                             TH
  605472   USHER SYNDROME, IIC; USH2C                                                      GPR98
  605899   GLYCINE ENCEPHALOPATHY; GCE                                                     AMT
  605899   GLYCINE ENCEPHALOPATHY; GCE                                                     GCSH
  605899   GLYCINE ENCEPHALOPATHY; GCE                                                     GLDC
  606056   CONGENITAL DISORDER OF GLYCOSYLATION, IIb; CDG2B                                MOGS
  606353   PRIMARY LATERAL SCLEROSIS, JUVENILE; PLSJ                                       ALS2
  606369   EPILEPTIC ENCEPHALOPATHY, LENNOX-GASTAUT                                        MAPK10
  606407   HYPOTONIA-CYSTINURIA SYNDROME                                                   PREPL
  606407   HYPOTONIA-CYSTINURIA SYNDROME                                                   SLC3A1
  606612   MUSCULAR DYSTROPHY, CONGENITAL, 1C; MDC1C                                       FKRP
  606812   FUMARASE DEFICIENCY                                                             FH
  606943   USHER SYNDROME, IG; USH1G                                                       USH1G
  606966   NEPHRONOPHTHISIS 4; NPHP4                                                       NPHP4
  607014   HURLER SYNDROME                                                                 IDUA
  607091   CONGENITAL DISORDER OF GLYCOSYLATION, IId; CDG2D                                B4GALT1
  607095   ANAUXETIC DYSPLASIA                                                             RMRP
  607330   LATHOSTEROLOSIS                                                                 SC5DL
  607426   COENZYME Q10 DEFICIENCY                                                         APTX
  607426   COENZYME Q10 DEFICIENCY                                                         CABC1
  607426   COENZYME Q10 DEFICIENCY                                                         COQ2
  607426   COENZYME Q10 DEFICIENCY                                                         PDSS1
  607426   COENZYME Q10 DEFICIENCY                                                         PDSS2
  607598   ICOS DEFICIENCY; LCCS2                                                          ERBB3
  607616   NIEMANN-PICK DISEASE, B                                                         SMPD1
  607624   GRISCELLI SYNDROME, 2; GS2                                                      RAB27A
  607625   NIEMANN-PICK DISEASE, C2                                                        NPC2
  607626   ICHTHYOSIS, LEUKOCYTE VACUOLES, ALOPECIA, AND SCLEROSING CHOLANGITIS            CLDN1
  607655   SKIN FRAGILITY-WOOLLY HAIR SYNDROME                                             DSP
  607855   MUSCULAR DYSTROPHY, CONGENITAL MEROSIN-DEFICIENT, 1A; MDC1A                     LAMA2
  608013   GAUCHER DISEASE, PERINATAL LETHAL                                               GBA
  608093   CONGENITAL DISORDER OF GLYCOSYLATION, Ij; CDG1J                                 DPAGT1
  608099   MUSCULAR DYSTROPHY, LIMB-GIRDLE, 2D; LGMD2D                                     SGCA
  608456   COLORECTAL ADENOMATOUS POLYPOSIS, AR                                            MUTYH
  608540   CONGENITAL DISORDER OF GLYCOSYLATION, Ik; CDG1K                                 ALG1
  608612   MANDIBULOACRAL DYSPLASIA WITH B LIPODYSTROPHY; MADB                             ZMPSTE24
  608629   JOUBERT SYNDROME 3; JBTS3                                                       AHI1
  608643   AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY                                  DDC
  608688   AICAR TRANSYLASE/IMP CYCLOHYDROLASE, DEFICIENCY OF                              ATIC
  608782   PYRUVATE DEHYDROGENASE PHOSPHATASE DEFICIENCY                                   PDP1
  608799   CONGENITAL DISORDER OF GLYCOSYLATION, Ie; CDG1E                                 DPM1
  608800   SUDDEN INFANT DEATH WITH DYSGENESIS OF THE TESTES SYNDROME; SIDDT               TSPYL1
  608804   LEUKODYSTROPHY, HYPOMYELINATING, 2                                              GJC2
  608836   CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL                   CPT2
  608840   MUSCULAR DYSTROPHY, CONGENITAL, 1D                                              LARGE
  609015   TRIFUNCTIONAL PROTEIN DEFICIENCY                                                HADHA
  609015   TRIFUNCTIONAL PROTEIN DEFICIENCY                                                HADHB
  609016   LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY                           HADHA
  609049   PIERSON SYNDROME                                                                LAMB2
  609056   AMISH INFANTILE EPILEPSY SYNDROME                                               ST3GAL5
  609060   COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 1; COXPD1                         GFM1
  609241   SCHINDLER DISEASE, I                                                            NAGA
  609254   SENIOR-LOKEN SYNDROME 5; SLSN5                                                  IQCB1
  609304   EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 3                                    SLC25A22
  609311   CHARCOT-MARIE-TOOTH DISEASE, 4H; CMT4H                                          FGD4
  609528   CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, PALMOPLANTAR KERATODERMA           SNAP29
  609560   MITOCHONDRIAL DNA DEPLETION SYNDROME, MYOPATHIC                                 TK2
  609583   JOUBERT SYNDROME 4; JBTS4                                                       NPHP1
  609638   EPIDERMOLYSIS BULLOSA, LETHAL ACANTHOLYTIC                                      DSP
  610003   CEROID LIPOFUSCINOSIS, NEURONAL, 8, NORTHERN EPILEPSY                           CLN8
  610006   2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY                                    ACADSB
  610090   PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY                               PNPO
  610127   CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10                                      CTSD
  610188   JOUBERT SYNDROME 5; JBTS5                                                       CEP290
  610198   3-METHYLGLUTACONIC ACIDURIA, V                                                  DNAJC19
  610370   DIARRHEA 4, MALABSORPTIVE, CONGENITAL                                           NEUROG3
  610377   MEVALONIC ACIDURIA                                                              MVK
  610498   COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 2; COXPD2                         MRPS16
  610505   COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 3; COXPD3                         TSFM
  610532   LEUKODYSTROPHY, HYPOMYELINATING, 5                                              FAM126A
  610651   XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP B; XPB                             ERCC3
  610688   JOUBERT SYNDROME 6; JBTS6                                                       TMEM67
  610725   NEPHROTIC SYNDROME, 3; NPHS3                                                    PLCE1
  610768   CONGENITAL DISORDER OF GLYCOSYLATION, Im; CDG1M                                 DOLK
  610854   OSTEOGENESIS IMPERFECTA, IIB                                                    CRTAP
  610915   OSTEOGENESIS IMPERFECTA, VIII                                                   LEPRE1
  610951   CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7                                        MFSD8
  610992   PHOSPHOSERINE AMINOTRANSFERASE DEFICIENCY                                       PSAT1
  611067   SPINAL MUSCULAR ATROPHY, DISTAL, AR, 4; DSMA4                                   PLEKHG5
  611126   ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY OF                          ACAD9
  611561   MECKEL SYNDROME, 5; MKS5                                                        RPGRIP1L
  611705   MYOPATHY, EARLY-ONSET, WITH FATAL CARDIOMYOPATHY                                TTN
  611719   COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 5; COXPD5                         MRPS22
  611721   COMBINED SAPOSIN DEFICIENCY                                                     PSAP
  611722   KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY                           PSAP
  611726   EPILEPSY, PROGRESSIVE MYOCLONIC 3; EPM3                                         KCTD7
  612164   EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 4                                    STXBP1
  612304   THROMBOPHILIA, HEREDITARY, DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL               PROC
  612416   FACTOR XI DEFICIENCY                                                            F11
  -------- ------------------------------------------------------------------------------- -----------
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